LINC01299: A Potential Drug Target and Biomarker (G286186)

Target Name: LINC01299

NCBI ID: G286186

LINC01299

Other Name(s): Long intergenic non-protein coding RNA 1299 | CTD-3025N20.2 | long intergenic non-protein coding RNA 1299

LINC01299: A Potential Drug Target and Biomarker

LINC01299 is a non-coding RNA (ncRNA) molecule that has been identified using RNA sequencing (RNA-seq) data. It is located within the gene cluster on chromosome 6q24, which is known as the default gene cluster. This gene has been annotated as a long intergenic non-protein coding RNA (lncRNA), which means that it is not a protein-coding gene but is involved in the regulation of gene expression.

The discovery of LINC01299 and its properties have raised the possibility that it may be a drug target or a biomarker. In this article, we will explore the potential implications of LINC01299 as a drug target and biomarker.

Potential Drug Target

The potential drug target for LINC01299 is based on its expression level. LINC01299 is expressed in most tissues of the body and is highly expressed in the brain. It is also highly expressed in tissues that are known to be sensitive to drugs such as chemotherapy, such as the breast tissue and the brain.

The expression of LINC01299 is also correlated with the expression of the protein encoded by its gene, which is known as PIM1. PIM1 is a protein that is known to play a role in cell signaling and is involved in the regulation of cell growth, differentiation, and survival.

Studies have shown that LINC01299 is a good candidate for a drug target because it is involved in the regulation of cellular processes that are sensitive to drugs. Additionally, its expression is also associated with the expression of other proteins that are known to be drug targets, such as PIK3CA, TCF7L1, and NF1.

Potential Biomarker

LINC01299 has also been identified as a potential biomarker for cancer. The expression of LINC01299 is correlated with the expression of genes that are known to be involved in cancer development, such as the TP53 gene. TP53 is a gene that is known to play a critical role in the regulation of cell growth and is often mutated in cancer.

The expression of LINC01299 has also been correlated with the expression of genes that are known to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These mutations have been shown to be associated with the decreased expression of LINC01299.

Conclusion

In conclusion, LINC01299 is a non-coding RNA molecule that has been identified using RNA-seq data. Its expression is associated with the regulation of cellular processes that are sensitive to drugs and with the expression of proteins that are known to be drug targets. Additionally, its expression is also associated with the expression of genes that are known to be involved in cancer development and neurodegenerative diseases. These properties make LINC01299 a potential drug target and biomarker. Further studies are needed to confirm its potential as a drug.

Protein Name: Long Intergenic Non-protein Coding RNA 1299

The "LINC01299 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01299 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets